{"nctId":"NCT01189487","briefTitle":"The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)","startDateStruct":{"date":"2010-10"},"conditions":["Pneumonia, Bacterial"],"count":47,"armGroups":[{"label":"ampicillin sodium/sulbactam sodium","type":"EXPERIMENTAL","interventionNames":["Drug: ampicillin sodium/sulbactam sodium"]}],"interventions":[{"name":"ampicillin sodium/sulbactam sodium","otherNames":["Unasyn-S"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 16 years of age or older.\n* Patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam sodium, other penicillins, or cephems.\n* Hepatic dysfunction \\[Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT), total bilirubin \\> 3 times upper limit of normal range values\\].\n* Severe renal dysfunction (creatinine clearance \\< 30 ml/min).\n* Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"79 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate (Clinical Response, Data Review Committee Assessment)","description":"Response rate was calculated from the following formula, \"the number of participants assessed as effective\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate (Clinical Response, Investigator Assessment)","description":"Response rate was calculated from the following formula, \"the number of participants assessed as effective\" over \"total participants EXCLUDING ones assessed as indeterminate\" multiplied by 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Tendency Toward Clinical Improvement (Investigator Assessment)","description":"The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 4 and was determined to continue the treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Eradication Rate (Bacteriological Response, Data Review Committee Assessment)","description":"Eradication Rate was calculated from the following formula, \"the number of participants assessed as eradication, presumed eradication or microbial substitution\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Eradication Rate (Bacteriological Response, Investigator Assessment)","description":"Eradication Rate was calculated from the following formula, \"the number of participants assessed as eradication , presumed eradication or microbial substitution\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Constipation","Blood alkaline phosphatase increased","Diarrhoea"]}}}